secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000950170-24-021650
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed reports FY2023 net loss $95.7M; Phase2b MM120 shows 7.6-point HAM-A reduction for GAD
--------------------------------------------------------------------------------

- Cash and equivalents $99.7M vs $142.1M at Dec 2022; expected to fund operations into 2026.
- Net loss $95.7M vs $56.8M in 2022; R&D expenses $52.1M (up $15.9M) driven by MM120 Phase 2b trial.
- Phase 2b MM120 (100 µg) achieved 7.6-point HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response rate.
- Plans End-of-Phase 2 FDA meeting H1 2024, Phase 3 MM120 GAD program start H2 2024; March 7 investor event for 12-week data.
- Initiated Phase 1 trial of MM402 (R(-)-MDMA) for ASD in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024021650/0000950170-24-021650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024021650/mnmd-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer